Sainte Foy, Canada Clinical Trials

A listing of Sainte Foy, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 120 clinical trials
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) …

brain metastases
progesterone receptor
taxane
metastasis
breast carcinoma
Hopital du Saint-Sacrement, CHU de Quebec-Universite Laval
 (2.2 away) Contact site
  • 24 views
  • 15 Sep, 2021
  • +234 other locations
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and enzalutamide in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy for mCRPC, are abiraterone-nave, or are intolerant to or progressed on abiraterone acetate. There …

diphosphonates
metastasis
adenocarcinoma of prostate
tumor progression
castration-resistant prostate cancer
CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 0103)
 (4.2 away) Contact site
  • 506 views
  • 05 Sep, 2021
  • +253 other locations
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

Phase 3 study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (300/L). Eligible patients must have a history of 2 moderate and/or severe COPD exacerbations in the previous year …

eosinophil count
antibiotics
severe chronic obstructive pulmonary disease
bronchodilator
corticosteroids
Research Site
 (0.8 away) Contact site
  • 838 views
  • 10 Sep, 2021
  • +438 other locations
A Multicenter Randomized Double-Blind Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the appropriate induction dose of risankizumab for further evaluation in Sub-Study 2. The objective of Sub-Study 2 is to …

remission
Hopital Hotel-Dieu de Levis /ID# 214378
 (5.6 away) Contact site
  • 618 views
  • 15 Sep, 2021
  • +926 other locations
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation …

acute coronary syndrome
infarct
diabetes
percutaneous coronary intervention
arterial disease
1240071 - Institut universitaire de cardiologie et de pneumologie de Quebec
 (0.7 away) Contact site
  • 1131 views
  • 15 Sep, 2021
  • +3432 other locations
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. …

cardiovascular disease
overweight or obesity
body mass index
Novo Nordisk Investigational Site
 (0.7 away) Contact site
  • 7753 views
  • 12 Sep, 2021
  • +1166 other locations
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced …

metastasis
lung carcinoma
platinum doublet
chemoradiotherapy
pemetrexed
CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 0110)
 (4.2 away) Contact site
  • 51 views
  • 12 Sep, 2021
  • +191 other locations
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.

cardiovascular disease
hemoglobin a1c
body mass index
CR A&E Centre de Recherche Inc.
 (2.7 away) Contact site
  • 597 views
  • 12 Sep, 2021
  • +895 other locations
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab.

alzheimer's disease
mini-mental state examination
flortaucipir
florbetapir
positron emission tomography
Alpha Recherche Clinique Lebourgneuf
 (4.1 away) Contact site
  • 89 views
  • 12 Sep, 2021
  • +394 other locations
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS) is a group of disorders that gradually affect the ability of a person's bone marrow (semi-liquid tissue present in many bones like backbones) to produce normal blood cells. Some people with MDS have a risk of the disease progressing to acute myeloid leukemia (AML), and a risk …

remission
myeloid leukemia
anemia
leukemia
azacitidine
CHU de Quebec Hopital de l'Enf /ID# 221200
 (4.7 away) Contact site
  • 27 views
  • 15 Sep, 2021
  • +343 other locations